Experimental CAR-T therapy takes on Hard-to-Treat myeloma
NCT ID NCT05577000
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new type of immune cell therapy called Anti-BCMA CAR-T cells in 5 adults with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy involves collecting a patient's own immune cells, modifying them to target a protein on myeloma cells, and infusing them back along with two chemotherapy drugs. The main goal is to check safety and find the right dose, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anti-BCMA CAR-T cells (a type of immune cell therapy) given with chemotherapy drugs fludarabine and cyclophosphamide
- What this could lead to
- If this works, it could point toward a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
- What could go wrong
- This is a very early, small phase 1b trial with only 5 participants, focused mainly on safety. The treatment may not work, and there are risks of serious side effects like cytokine release syndrome or nerve problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a One-Two drug punch beat back Hard-to-Treat myeloma?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Double-barreled CAR t therapy takes aim at hard-to-treat myeloma
- Can a drug stop dangerous side effects of new myeloma therapies?